{"denomUnitsSelected":"Participants","description":"Progression-Free Survival (PFS) was defined as the time from randomization (arm A) or crossover (arm D) to disease progression or death (whichever occurs first). Cases without an event to date was censored at the date of last disease assessment documenting the patient was free of progression. Progression was evaluated based on international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Median PFS was estimated using Kaplan-Meier method.","reportingStatus":"NOT_POSTED","timeFrame":"assessed at baseline and then every 12 weeks from start of treatment if patient is < 2 years from study entry (or < 2 years from crossover), then every 6 months until 5 years from study entry","title":"Median Progression-free Survival (Arm A vs Arm D)","type":"SECONDARY"}